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The effects of intravenous iron 
supplementation on fatigue 
and general health in non‑anemic 
blood donors with iron deficiency: 
a randomized placebo‑controlled 
superiority trial
Peter Keller1, Roland von Känel2*, Cesar A. Hincapié3,4, Bruno R. da Costa3,5, Peter Jüni3,5, 
Tobias E. Erlanger6, Nicola Andina7,8,9, Christoph Niederhauser10,11,12,13, Bernhard Lämmle 
7,14,15 & Stefano Fontana10,11
We investigated whether intravenous iron supplementation improves fatigue and general health in 
non‑anemic repeat adult blood donors with iron deficiency (ferritin ≤ 50 µg/L). Of 1,487 potentially 
eligible participants, 203 were randomly assigned to a single intravenous dose of 800 mg iron‑
carboxymaltose and 202 to placebo; 393 participants completed the trial. At 6 to 8 weeks after 
intervention, self‑rated mean fatigue scores (numeric rating scale from 1–10, primary outcome) were 
3.9 ± 1.8 in the iron supplementation group and 4.0 ± 2.2 in the placebo group, showing no group 
difference (p = 0.819). Pre‑specified subgroup analyses of gender, ferritin < 25 µg/L and fatigue ≥ 4 
points, as well as exploratory analyses of lower ferritin cut‑offs did not reveal any between‑group 
differences. In terms of secondary outcomes, the mean differences were 114.2 µg/L for ferritin (95% 
CI 103.1–125.3) and 5.7 g/L for hemoglobin (95% CI 4.3–7.2) with significantly higher values in the 
iron supplementation group. No group differences were observed for different measures of general 
well‑being and other clinical and safety outcomes. Intravenous iron supplementation compared with 
placebo resulted in increase of ferritin and hemoglobin levels in repeat blood donors with low iron 
stores, yet had no effect on fatigue and general well‑being.
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Each year, about 120 million blood donations are provided by tens of millions of blood donors around the  world1, 
enabling lifesaving transfusions and creating an invaluable resource for modern health systems. The safety and 
health of blood donors are therefore of great importance, and a better understanding of the health implications 
of blood donation is needed. Blood donation is associated with the loss of iron—every whole blood donation 
removes about 200–250 mg of elemental iron from the  body2. Consequently, the iron stores of many repeat blood 
donors are low or  depleted3,4. Among frequent donors in one US study, almost 20% and 30% of men and women, 
respectively, were found to have absent iron stores (ferritin < 12 µg/L)5. To prevent blood donation deferral due 
to iron deficiency anemia, measures to detect and correct low iron stores, including regular assessment of serum 
ferritin or iron  supplementation6–14, have been proposed as routine measures by blood  bankers15–17. Currently, 
however, iron supplementation for blood donors is not a standard of care in many blood donation services.
A syndrome of non-anemic iron deficiency (NAID) has been hypothesised as a potential factor leading to 
symptoms in the absence of anemia, especially given the essential role of iron in many metabolic pathways (e.g., 
mitochondrial  oxidases18, neurotransmitters, muscle metabolism, and  others19). NAID has been associated with 
 fatigue20–22, reduced quality of  life23, lower work  performance24, cognitive  changes25–27, mood  disturbances20,28, 
and restless legs syndrome and  pica29–31. However, few randomized clinical trials have examined participant 
reported outcomes, such as fatigue and general well-being, among blood donors receiving iron supplementation. 
In a Cochrane  review10, only two trials were found which had included health-related quality of life outcome 
measures in blood donors receiving iron  supplementation32,33.
We designed the Iron SUpplementation in Blood donors (ISUB) randomized controlled trial to assess the 
efficacy and safety of iron supplementation with intravenous ferric carboxymaltose in blood donors with NAID, 
focusing on participant reported outcomes of fatigue and well-being. In particular, we hypothesised a state of 
potentially impaired general well-being and increased fatigue due to NAID in repeat blood donors that might 
improve by intravenous iron supplementation. We used intravenous iron supplementation instead of oral sup-
plementation to ensure sufficient and rapid iron availability, as well as true blinding, as oral iron formulations 
may cause gastrointestinal side effects, potentially impairing treatment adherence, and lead to a black discolora-
tion of stool.
Results
Enrolment and follow‑up. Between December 6, 2011 and January 29, 2013, 405 participants underwent 
randomization: 203 were allocated to the experimental intervention and 202 to placebo (Fig. 1). One participant 
in the experimental group withdrew consent. Three and 4 participants had a protocol violation, and 198 (97.5%) 
and 195 participants (96.5%) provided primary outcome data at 6–8 weeks after randomization in experimental 
and control groups, respectively. All randomized patients were included in the intention-to-treat analysis. Base-
Figure 1.  The figure shows the flow of participants through the trial.
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line characteristics were similar in the two study groups (Table 1). The mean age was 42.2 years, the proportion 
of females 46.2%, and the mean number of blood donations over the past 2 years was 5. Mean hemoglobin on 
the day of treatment was 141.5 g/L in men and 125.0 g/L in women. We screened for iron deficiency 4 to 6 weeks 
prior to study enrolment on the occasion of a blood donation; the mean serum ferritin at this time point was 
28.1 µg/L, while it was 18.6 µg/L on the day of randomization and treatment. At the time of iron or placebo sup-
plementation, 176 (43.5%) blood donors had severe iron deficiency defined by ferritin < 15 µg/L.
Outcomes. The mean values of the primary outcome of self-rated fatigue and all secondary outcomes are 
presented in Table 2, separately for the iron supplementation group and the placebo group, and with mean dif-
ferences between groups. At 6 to 8 weeks after treatment, self-rated mean fatigue scores were 3.9 ± 1.8 in the 
iron supplementation group and 4.0 ± 2.2 in the placebo group, showing no group difference (mean difference 
− 0.04; 95% CI − 0.41 to 0.32; p = 0.813) (Fig. 2). Results were consistent for the other secondary donor reported 
outcomes at 6–8 weeks with no significant group differences. At 6–8 weeks the experimental group experienced 
a significantly larger increase in both serum ferritin (142.6 ± 54.5 µg/L vs. 28.6 ± 61.3 µg/L) and hemoglobin 
(142.7 ± 10.9 g/L vs. 137.2 ± 12.0 g/L) than the placebo group (mean differences 114.2 µg/L; 95% CI 103.1–125.3; 
p < 0.0001 for ferritin and 5.7 g/L; 95% CI 4.3–7.2; p < 0.0001 for hemoglobin) (Fig. 2). Pre-specified subgroup 
Table 1.  Baseline characteristics. Plus–minus values are means ± SD. There were no significant differences in 
baseline characteristics between the two randomly assigned groups. Percentages may not total 100 because 
of rounding a Self-rated fatigue during the past 7 days on a numeric rating scale ranging from 1 (no fatigue 
at all) to 10 (extreme fatigue). b 30-item Multidimensional Fatigue Symptom Inventory-Short-Form (MFSI) 
measures general, physical, emotional, and mental fatigue, and vigour in the previous seven days. Each 
subscale comprises six items rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely), yielding a total 
score between 0 and 24 for each subscale Total fatigue score is calculated by subtracting the vigour subscale 
score from the sum score of the other four subscales. c EQ-5D is a generic instrument used to measure current 
health status related to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each 
dimension is rated on three levels of perceived problems (with corresponding score): no problems (2), some 
or moderate problems (1), extreme problems (0), yielding a total standardized score between 0 and 10. Higher 
scores indicate better health status. The EQ-5D VAS allowed participants to rate their own health, ranging 
from 0 (worst imaginable health state) to 10 (best imaginable health state). d 27-item Symptom Checklist 
(SCL27) assesses general psychological distress based on depressive, anxiety, mistrust and vegetative symptoms 
in the previous week. Each item is rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Total 
distress scores are expressed as the mean value of the 27 items. e 4-item Jenkins Sleep Questionnaire (JSQ) rates 
subjective sleep quality in the previous month, referring to trouble falling asleep, trouble staying asleep (waking 
up far too soon and inability to fall back to sleep), waking up several times per night, and waking up feeling 
tired and worn out after the usual amount of sleep. Response options (with corresponding score): not at all (0), 
1–3 days (1), 4–7 days (2), 8–14 days (3), 15–21 days (4) and 22–31 days (5). Yields a total score between 0 to 
20, with higher scores indicating poorer sleep quality.
Characteristics Iron group (N = 203) Placebo group (N = 202)
Female—no. (%) 94 (46.3) 93 (46.0)
Age—year 42.1 ± 12.2 42.2 ± 12.3
Blood donations in the past 2 years 5.0 ± 1.9 5.3 ± 1.8
Fatigue levela 4.4 ± 2 4.6 ± 2
Fatigue level ≥ 4—no. (%) 116 (57.1) 116 (57.4)
Multidimensional fatigue symptom inventoryb—total 16.5 ± 15 16.1 ± 15
MFSI—general 10.7 ± 4 10.5 ± 4
MFSI—physical 8.3 ± 3 8.2 ± 3
MFSI—emotional 9.4 ± 3 9.0 ± 3
MFSI—mental 9.4 ± 3 9.4 ± 3
MFSI—vigour 21.5 ± 4 21.2 ± 4
EQ-5Dc index 9.2 ± 1 9.3 ± 1
EQ-5D visual analog scale 8.3 ± 1 8.4 ± 1
27-item symptom  checklistd (SCL27) 1.3 ± 0 1.3 ± 0
Jenkins Sleep  Scalee 9.6 ± 3 9.0 ± 3
Serum ferritin concentration at screening—µg/L 28.0 ± 12.2 28.2 ± 11.8
Serum ferritin concentration at baseline—µg/L 18.5 ± 9.8 18.7 ± 10.4
Ferritin < 25 µg/L at baseline—no. (%) 165 (81.3) 154 (76.6)
Ferritin < 15 µg/L at baseline—no. (%) 89 (43.8) 87 (43.3)
Hemoglobin concentration—g/L 133.8 ± 14.6 134.0 ± 12.6
Hemoglobin in males—g/L 142.5 ± 10.2 140.5 ± 10.4
Hemoglobin in females—g/L 123.6 ± 12.1 126.4 ± 10.5
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analyses of the primary outcome, including influence of gender (Fig. 3), of ferritin levels < 25 µg/L (Fig. 4) or of 
fatigue scores ≥ 4 (Fig. 3) did not show significant interactions with treatment. In addition, an exploratory sub-
group analysis based on serum ferritin levels < 20 µg/L, < 15 µg/L and < 10 µg/L did not show a relevant impact 
on estimated treatment effects (Fig. 4).
Safety outcomes. Table 3 presents adverse events. The total number of adverse events was greater in the 
iron supplementation group (n = 52) than in the placebo group (n = 29) (p = 0·019). Forty-one (20.2%) and 28 
participants (13.9%) reported an adverse event in the experimental and placebo groups, respectively (p = 0·090). 
In each group, we observed one grade-3 adverse event: 1 participant reported dizziness and headache after iron 
supplementation, and 1 participant experienced retinal detachment after receiving placebo. There were no seri-
ous adverse events or suspected unexpected severe adverse reactions. Events certainly or likely associated with 
treatment were not significantly different between the two groups.
Discussion
In repeat blood donors with low iron stores, we found that intravenous supplementation with 800 mg ferric 
carboxymaltose did not result in a clinically relevant decrease in self-perceived fatigue compared to placebo. 
Our trial also revealed no significant differences in physical, emotional, and mental fatigue, general psychologi-
cal distress, sleep quality, or general current health status between the iron and the placebo groups. Subgroup 
analyses of gender, participants with ferritin values < 25 µg/L, < 20 µg/L, < 15 µg/L and < 10 µg/L and baseline 
fatigue of ≥ 4 points on the NRS were consistent with our main findings of no significant difference between iron 
and placebo infusion groups.
Our findings align with an earlier, smaller study of oral iron replacement in iron-depleted blood  donors32, 
with a recent intravenous iron study in female first time donors, in which fatigue was measured as secondary 
 outcomes34, and with a large cohort study with more than 16,000 blood donors investigating the relationship 
between iron deficiency and self-reported mental or physical  health35. Together, the evidence from these stud-
ies does not support the idea that NAID is a generalizable health problem in blood donors. In contrast, intra-
venous iron slightly increased hemoglobin and normalized ferritin in the iron supplementation group, while 
both parameters were unchanged in the placebo group. While these findings are compatible with the presence 
of a functional iron deficiency in erythropoietic cells, the absence of an improvement in participant reported 
outcomes of fatigue and general well-being suggests that functional iron deficiency in other tissues may not be a 
clinically relevant concept. We observed a rather low mean hemoglobin level in the lower range of normal in the 
study participants at baseline (Table 1). Although we enrolled the donors 4–6 weeks after the last blood dona-
tion, an ongoing decrease of the hemoglobin level by the donation is still possible. The increase of hemoglobin 
levels in the participants receiving iron supplementation suggests that individualised target hemoglobin levels 
for some repeat blood donors may be more appropriate.
Our findings vary compared to studies in premenopausal non-donor women that found a decrease of fatigue 
after iron  supplementation20,36–38. In this specific population, studies with oral iron supplementation found 
a treatment effect on fatigue even in participants with very moderate iron deficiency of serum ferritin levels 
up to 50 µg/L21,36. With intravenous iron, an effect was only demonstrated when the deficiency was severe 
Table 2.  Primary and secondary outcomes. Plus–minus values are means ± SD. Continuous outcomes were 
analysed using analyses of covariance adjusted for the outcome’s baseline values and stratification variables. See 
legend to Table 1 for explanations of abbreviations. a Self-perceived change in fatigue between baseline and 
6–8 weeks after randomization, assessed on a NRS between − 10 and + 10.
Outcome Iron group (N = 203) Placebo group (N = 202) Mean difference (95% CI)
Primary outcome
Fatigue level 3.9 ± 1.8 4.0 ± 2.2 0.0 (− 0.4 to 0.3)
Secondary outcomes
Change in  fatiguea − 0.6 ± 0.7 − 0.8 ± 2.2 0.1 (− 0.3 to 0.6)
 MFSI—total 11.0 ± 12.0 11.3 ± 12.3 − 0.4 (− 2.3 to 1.5)
 MFSI—general 9.2 ± 3.3 9.3 ± 4.0 − 0.1 (− 0.7 to 0.5)
 MFSI—physical 7.3 ± 2.2 7.3 ± 1.8 0.0 (− 0.3 to 0.3)
 MFSI—emotional 8.3 ± 2.9 8.1 ± 2.9 0.1 (− 0.4 to 0.6)
 MFSI—mental 8.6 ± 2.5 8.5 ± 2.5 0.2 (− 0.2 to 0.6)
 MFSI—vigour 22.4 ± 4.0 22.1 ± 4.7 0.0 (− 0.7 to 0.8)
EQ-5D index 9.5 ± 1.1 9.6 ± 1.1 − 0.1 (− 0.3 to 0.1)
EQ-5D visual analog scale 8.5 ± 1.1 8.4 ± 1.1 0.1 (− 0.1 to 0.3)
27-item symptom checklist (SCL27) 1.2 ± 0.0 1.2 ± 0.4 0.0 (− 0.0 to 0.0)
Jenkins sleep scale 8.5 ± 3.3 8.3 ± 2.9 − 0.2 (− 0.6 to 0.3)
Serum ferritin concentration—µg/L 142.6 ± 54.5 28.6 ± 61.3 114.2 (103.1 to 125.3)
Hemoglobin concentration—g/L 142.7 ± 10.9 137.2 ± 12.0 5.7 (4.3 to 7.2)
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(ferritin < 15 µg/L)37,38. The difference may indicate a reporting bias among participants who deduced their 
Figure 2.  Self-rated fatigue, hemoglobin and ferritin levels at baseline and follow-up (6–8 weeks after 
randomization) in the iron and placebo groups. Data points are means; bars indicate 95% confidence intervals.
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:14219  | https://doi.org/10.1038/s41598-020-71048-0
www.nature.com/scientificreports/
treatment allocation, demonstrating the impact of incomplete blinding due to the treatment-related symptoms 
in trials using oral iron supplementation.
Our findings need to be discussed in the context of the INTERVAL parallel group, pragmatic, randomized 
trial which had included over 45,000 male and female whole blood donors across  England14. In that trial, a 
reduction in inter-donation intervals over 2 years resulted in a modest increase in the prevalence of symptoms 
potentially related to blood donation, including self-reported tiredness. Although participants feeling more 
tired than usual had lower ferritin levels at 2-year examination, decrease in serum ferritin and hemoglobin 
concentrations explained only a small part of the symptoms linked with increased frequency donation. There 
could also be alterations in metabolic, immune and neurological pathways due to the shortening of donation 
intervals contributing to fatigue which are not directly related to the ferritin concentration. The role of the brain 
as an active organ for homeostatic control in the perception of bodily symptoms like fatigue is increasingly 
Figure 3.  Forest plot of the primary outcome analysis for self-rated fatigue (numerical rating scale of 1–10 
points) 6–8 weeks after randomization (overall) and the prespecified subgroup analyses according to baseline 
fatigue (< 4 vs. ≥ 4 points), ferritin level (< 25 µg/L vs. ≥ 25 µg/L), and gender. Mean differences with 95% 
confidence intervals are depicted. p values are for tests of interaction between the two treatment groups.
Figure 4.  Forest plot of self-rated fatigue at follow-up for lower serum ferritin concentration level cut-offs 
of < 25, < 20, < 15 and < 10 µg/L. Shown are mean differences between iron supplementation and placebo groups 
with 95% confidence intervals and number of participants per subgroup. p values are for tests of interaction 
between the two treatment groups.
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 acknowledged39. In this understanding, a sustained deviation of autonomic, neuroendocrine and immunological 
states will prompt the brain to generate for instance fatigue, motivating a person to exercise adaptive behaviors 
in order to alleviate  fatigue40.
Strength and limitations. Our study was well blinded for both participants and study personnel and miti-
gated reporting bias, overcoming shortcomings in patient blinding due to gastrointestinal symptoms, including 
change of stool colour, in previous trials using oral iron  supplementation21,32,36,41, or from the lack of investigator 
blinding in another trial of intravenous  iron38. The loss of information due to attrition was very low, highlight-
ing the quality of our data. In contrast to an earlier study in blood donors (32) and studies in premenopausal 
women with  fatigue21,36–38, we included an almost equal number of male iron-depleted participants, helping to 
fill in this data and information gap. A limitation of our design may be the relatively high ferritin level (50 µg/L) 
for study inclusion, chosen on the basis of other studies on iron  supplementation36,37. However, the pre-specified 
subgroup analysis of the primary outcome in donors with ferritin levels < 25 µg/L did not show significant inter-
actions with treatment (Fig. 3). Furthermore, larger changes in self-reported fatigue should have been detectable, 
if present, due to the high number of study participants, the low mean ferritin level of the study population at 
baseline and the high number of participants with ferritin < 15  µg/L. However, we cannot rule out the pos-
sibility that blood donors with very high fatigue scores may benefit from iron supplementation. Nonetheless, 
there was no significant decrease in fatigue with iron supplementation in the subgroup of blood donors with a 
fatigue score ≥ 4 (n = 232; 57.3%), although statistical power was limited for this analysis. We assessed treatment 
response 6–8 weeks after iron or placebo infusion, but it may take several weeks longer for the fatigue-decreasing 
effect of iron supplementation to become fully apparent, as was suggested by a recent uncontrolled open-label 
 study42. We did not investigate other outcomes, including cognition, restless legs syndrome and mood; for the 
latter two, sleep quality and general psychological distress are only proxy measures. Whether our findings are 
also applicable to non-anemic, non-donor premenopausal women with decreased ferritin levels would need to 
be explored in a subsequent randomized trial, as this intervention is widely used.
Conclusions and implications for practice. Intravenous iron supplementation with iron carboxymalt-
ose in repeat blood donors with iron deficiency without anemia had no effect on self-reported fatigue or general 
well-being, compared with placebo, although it was well tolerated in most participants. Our findings are not 
compatible with the notion of a NAID syndrome as a general problem in otherwise healthy, asymptomatic repeat 
blood donors. Besides short-lived effects immediately after phlebotomy, depleted iron stores of repeat blood 
donors were not found to be associated with self-rated fatigue or impaired general health. Our results do not 
support practices of regular ferritin monitoring or prophylactic iron supplementation in repeat blood donors 
without anemia. Even when ferritin levels are demonstrated to be low, iron supplementation cannot be recom-
mended to improve self-reported fatigue or low general well-being in repeat blood donors.
Methods
Study design. ISUB was an investigator-initiated randomized single-centre placebo-controlled, superiority 
trial in healthy blood donors with depleted iron stores (ferritin ≤ 50 µg/L), comparing intravenous iron supple-
mentation versus placebo. The trial was conducted in accordance with the Declaration of Helsinki and approved 
Table 3.  Adverse events. Adverse events were rated by the principal investigator according to National Cancer 
Institute, Common Terminology Criteria for Adverse Events, version 3.0. a Certainly or likely related to the 
study drug as rated by the principal investigator. *p value calculated using the chi-squared test. **p value 
calculated using repeated measures ANOVA.
Event Iron (N = 203) Placebo (N = 202) p value
All adverse events
Number of participants reporting events—N (%) 41 (20.2) 28 (13.9) 0.090*
Total number of adverse events—N 52 29 0.019**
Number of ≥ grade 3 adverse events—N 1 1
Number of serious adverse events—N 0 0
Drug associated adverse eventsa
Number of participants reporting events—N (%) 10(4.9) 9(4.5) 0.820*
Total number of adverse events—N 15 9 0.320**
 Allergic reaction or bronchospasm 2 0
 Fatigue or insomnia 4 4
 Gastrointestinal symptoms 2 1
 Respiratory symptoms 2 0
 Neuropathy or taste alteration 3 3
 Palpitation 1 0
 Rash 1 1
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by the research ethics committee of the Canton of Bern (#010/11) and the Swiss Agency for Therapeutic Prod-
ucts, Swissmedic (2011DR3145). The study was registered with ClinicalTrials.gov, Number NCT01519830 on 
01/27/2012. The CONSORT Checklist with information reported in this trial can be found as Supplementary 
Table 1S.
Study participants. Blood donors who visited the blood donation centre of the Interregional Blood Trans-
fusion Service of the Swiss Red Cross in Bern, Switzerland, were screened for iron deficiency. Capillary blood 
was collected to assess hemoglobin, and venous blood to measure serum ferritin. We enrolled men and women 
blood donors aged between 18 and 70 years, with a serum ferritin ≤ 50 μg/L, for whom this was not their first 
blood donation. Excluded were donors with anemia (hemoglobin level < 121 g/L for women; < 135 g/L for men), 
history of anaphylaxis, acute systemic infection of any kind, iron overload, intolerance of intravenous iron sup-
plements, evidence of acute or chronic bleeding (especially gastrointestinal), disease or medication causing 
fatigue (judgement of the study physician), disease or medication not compatible with intravenous iron supple-
mentation (judgement of the study physician), underweight (< 50 kg), overweight (> 85 kg for women, > 100 kg 
for men), pregnancy or breast feeding, and those unable to understand the questionnaire or to give informed 
consent. All participants provided written informed consent for both screening and the trial.
Randomization and masking. Participants were centrally randomized 1:1 to receive intravenous iron 
or placebo using a locked, concealed web-based system (WebSpirit, 2mt Software GmbH, Ulm, Germany). 
Randomization was computer-generated, stratified by ferritin level (≤ 25  μg/L versus > 25  μg/L), gender, and 
fatigue [< 4 points versus ≥ 4 points on a 10-point numeric rating scale (NRS)]. Trial treatment assignment was 
double-blinded, so that neither study physicians and nurses involved in donor care and outcome assessment, 
nor participants were aware of treatment assigned. Intervention infusions were prepared in a separate building 
and administered by an independent team of study nurses, who provided no other care for study participants. 
To prevent unblinding by the colour of the trial infusion, infusion bags and injection sites were covered and 
nontransparent tubing was used to administer the study drug. The remaining study personnel performing data 
entry, queries and data management, and the statistician were all blinded to the allocated intervention until all 
primary and secondary analyses were completed.
Intervention. Four to six weeks after the initial eligibility assessment and last blood donation, 800 mg ferric 
carboxymaltose (Ferinject) in 200 ml 0.9% sodium chloride solution or placebo (200 ml 0.9% sodium chloride 
solution) were administered intravenously over a period of 15 min. The interval of 4–6 weeks between the last 
blood donation/enrollment and iron supplementation was chosen to allow adequate red blood cell replacement 
and taking into account the fact that with a longer time interval, the ferritin level at screening could be increas-
ingly influenced by various factors, including dietary changes. In accordance with clinical recommendations, 
the dose of 800 mg intravenous iron was chosen to guarantee adequate iron supplementation in heavy males, 
while posing no danger of iron overload in even the lightest study participants. To prevent distortion of study 
end points, additional blood donation was not allowed until outcome assessment was conducted 6–8 weeks later.
Procedures. Eligible donors were invited by phone to participate in the trial and received information about 
the trial by mail. At a first visit 4–6 weeks after the last blood donation informed consent was obtained and a new 
blood sample analysed. Pregnancy was excluded in women of child-bearing age with a urine-based pregnancy 
test. The participant completed the psychometric questionnaire and received the infusion of the study drug. A 
second visit to assess treatment response was scheduled 6–8 weeks after infusion. At this visit, we also repeated 
blood sampling and completion of the psychometric questionnaire and assessed adverse events.
Laboratory analyses were performed at the first visit before treatment and at the second visit. One 2.7 ml 
tube containing EDTA was drawn for full blood count (Advia 2120i, Siemens Healthcare, Zürich, Switzerland). 
The serum resulting from a 10 mL blood tube without anticoagulant was frozen in aliquots at − 70 °C and used 
for later batch analysis of serum ferritin (FERR4 Cobas on a Hitachi 912 analyzer, Roche Diagnostics GmbH, 
Mannheim, Germany).
Outcomes. The pre-specified primary outcome was self-rated average fatigue during the past 7  days, 
assessed 6–8 weeks after randomization and infusion of either iron or placebo, using a numeric rating scale 
(NRS) from 1 (no fatigue at all) to 10 (extreme fatigue)21. Secondary outcomes were self-perceived change in 
fatigue between baseline and 6–8 weeks after randomization, assessed on a NRS between − 10 and + 10; general 
well-being 6–8 weeks after randomization, measured by several validated self-rating questionnaires (30-item 
Multidimensional Fatigue Symptom Inventory-Short-Form (MFSI-SF)43,44, 27-item Symptom Checklist (SCL-
27)45, 4-item Jenkins Sleep Questionnaire (JSQ)46,47, EuroQol-5D (EQ-5D)48); and blood parameters (hemo-
globin and ferritin levels) 6–8  weeks after randomization. Safety outcomes were any adverse events, serious 
adverse events, and drug-associated adverse events reported by the participants after study drug infusion at the 
first visit and during outcome assessment at the second visit. These were rated by the principal investigator (PK) 
according to National Cancer Institute, Common Terminology Criteria for Adverse Events, version 3.049. The 
study nurse and principal investigator were masked to the assigned treatment.
Statistical analysis. A sample size of 163 participants per group yielded > 95% power to detect a clinically 
relevant difference of 1.0 on the 10-point fatigue NRS ranging from 1 to 10 at a two-sided alpha of 0.05, assum-
ing a typical standard deviation of 2.5. The number of participants per trial arm was increased to 200, to enable 
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us to detect a statistical interaction in subgroups with approximately 85% power, assuming a difference in the 
fatigue rating score of > 1.5 points. The protocol pre-specified the use of analyses of covariance for all continuous 
outcomes, adjusted for the outcome’s baseline values.
We performed pre-specified subgroup analyses and interaction tests according to ferritin at baseline (≤ 25 μg/L 
vs.  > 25 μg/L), gender, and fatigue at baseline (< 4 vs.  ≥ 4 points on the NRS). Analyses were based on the 
intention-to-treat principle, including all randomized patients according to their  allocation50, using multiple 
imputation to impute missing outcome  data51. We conducted a sensitivity analysis based on the per-protocol 
patient population. P-values and 95% confidence intervals (CIs) are two-sided. Analyses were performed in 
Stata version 12 software (StataCorp, College Station, Texas, USA) by an independent statistician of an academic 
clinical trials unit (CTU Bern, Switzerland) who was unaware of group assignment. Data were interpreted and 
conclusions formulated prior to unblinding investigators.
Data availability
Deidentified individual participant data and the data analysis plan are available from the corresponding author 
on reasonable request.
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